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Abstract 
Growing evidence from recent studies has revealed that microRNA-203 (miR-203) might be an attractive prognostic 
biomarker for cancer. But controversy still remains. The aim of this meta-analysis was to summarize available evidences 
and clarify the preliminary predictive value of miR-203 for prognosis in cancer patients. Eligible studies were identified 
through multiple research strategies in PubMed, EMBASE and Web of Science up to October 2015. Key statistics such 
as pooled hazard ratios (HR) with 95 % confidence intervals (CIs) were utilized to calculate patient survival. 13 eligi-
ble studies with 1600 patients were ultimately enrolled in this meta-analysis. Our results failed to show a significant 
relation between upregulated miR-203 expression and a favorable overall survival (OS) (HR 1.00, 95 % CI 0.65–1.36) in 
a random effect model. However, in subgroup analysis, we found that high expression of miR-203 was significantly 
associated with poor OS in Caucasian patients (HR 1.31, 95 % CI 1.06–1.55). In contrast, for Asian patients, over-expres-
sion of miR-203 was an independent prognostic factor for better and OS (HR 0.59, 95 % CI 0.22–0.96). It also sug-
gested that cancer types and miRNA assay method were significant associated with prognosis. The over-expression of 
miR-203 was effectively predictive of worse prognosis in breast cancer (HR 6.35, 95 % CI 1.34–11.36), pancreatic cancer 
(HR 1.19, 95 % CI 1.08–1.30), ependymoma (HR 1.35, 95 % CI 1.10–1.61), but for glioma patients, elevated miR-203 is 
a potential biomarker for predicting better progression of cancer (HR 0.26, 95 % CI −0.02 to 0.54). Besides, for direct 
miRNA profiling studies, over-expression of miR-203 was an independent prognostic factor for worse OS (HR 6.35, 
95 % CI 1.34–11.36). This meta-analysis indicated that ethnicity, tumor type and miRNA assay method mainly contrib-
uted to heterogeneity. Considering the insufficient evidence, further relevant studies are warranted.
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Background
MicroRNAs (miRNAs) represent a class of non-coding, 
highly conserved single stranded RNAs of approximately 
22 nucleotides (Fabian and Sonenberg 2012; Guo et  al. 
2016; Bartel 2004; Carthew and Sontheimer 2009). These 
tiny regulators mainly function via post-transcriptionally 
regulating gene expression at the posttranscriptional level 
(He and Hannon 2004; Garzon et  al. 2006; Rolle et  al. 
2016). They are thought modulate protein production 
by binding to complementary sites of target messenger 
RNAs (mRNAs), leading to degradation or transcrip-
tional gene silencing of mRNAs (Filipowicz et al. 2008). 
In light of previous reports that most human miRNAs are 
located at cancer associated regions of the genome, it can 
be speculated that miRNAs may be extensively involved 
in cancers (Calin et  al. 2005; Macfarlane and Murphy 
2010; Jonckheere et  al. 2015). In recent years, profil-
ing studies have confirmed that miRNAs are aberrantly 
expressed in various human cancers and are implicated 
in tumor progression and metastasis (Manikandan et al. 
2008; Lu et al. 2005; Cheng 2015).
Mir-203, located at the chromosome 14q32.33, is one 
of the most frequently mentioned miRNAs. Previous 
studies have showed that miR-203 exhibited aberrant 
expression in multiple malignancies compared with their 
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normal tissue, including gastric cancer (Imaoka et  al. 
2015), pancreatic adenocarcinoma (Ikenaga et  al. 2010) 
and colon carcinoma (Schetter et  al. 2008). Many stud-
ies have revealed that miR-203 plays an essential role 
during cell growth, migration, invasion (Viticchie et  al. 
2011; Wang et  al. 2013a). Studies also demonstrate that 
miR-203 acts as a tumor suppressor in tumor progres-
sion (Wang et  al. 2014). Therefore, it is hypothesized 
that miR-203 might be a potential prognostic markers in 
carcinoma.
Although various studies have focused on the prognos-
tic role of miR-203 in cancer, the conclusion remained 
inconsistent. In the current study, we carried out a 
meta-analysis to evaluate and predict the overall risk of 
elevated miR-203 expression for survival in patients with 
cancer. In addition, we also explored the implications and 
feasibility of utilizing miRNA-203 as a prognostic marker 
in clinical practice.
Methods
We performed this meta-analysis following the guide-
lines of the Meta-analysis of Observational Studies in 
Epidemiology group (MOOSE) (Stroup et al. 2000).
Search strategy and study selection
We systematically searched online databases, includ-
ing PubMed (http://www.ncbi.nlm.nih.gov/pubmed/), 
EMBASE (http://store.elsevier.com/embase) and Web 
of Science (www.isiknowledge.com), to identify relevant 
studies published before 6 October 2013. The search 
strategy included the following combinations of the key-
words: ‘microRNA 203’, ‘cancer OR carcinoma OR tumor 
OR malignancy’ and ‘prognosis OR survival OR mortality 
OR death OR relapse OR recurrence OR outcome’. The 
titles, abstracts, full texts and reference lists of retrieved 
articles were carefully scanned to identify additional eli-
gible studies.
Eligible studies had to meet the following criteria: (1) 
English publications; (2) a focus on patients with any 
type of carcinoma; (3) the association between miR-203 
expression and survival outcome. Other exclusion crite-
ria included studies were: (1) review articles or letters; (2) 
duplicate publications; (3) lacked sufficient data.
Data extraction and quality assessment
For each included study, the following data elements was 
collected: trial features (e.g., the first author and pub-
lication year); characteristics of the participants (e.g., 
ethnicity, pathological type, sample category, mean age 
and gender ratio); detection method; follow-up time 
and data needed for prognosis meta-analysis [e.g., haz-
ard ratios (HR), overall survival (OS) along with their 
95  % CIs and P values]. An HR of >1 was considered 
significant association with increasing risk of mortal-
ity or recurrence. If only Kaplan–Meier curves were 
reported, the data were extracted from graphical survival 
plots and HR was estimated using previously described 
methods (Williamson et  al. 2002; Tierney et  al. 2007). 
The methodological quality of all the studies included 
was assessed according a critical review checklist of the 
Dutch Cochrane Centre proposed by MOOSE (Stroup 
et al. 2000).
Statistical analysis
HR and 95  % confidence interval (CI) were conducted 
as Tierney’s method (Tierney et al. 2007). A test of het-
erogeneity for pooled HR was carried out by Cochran’s Q 
test and Higgins I-squared statistic. If heterogeneity was 
observed (P  <  0.05), a random effect model (Der Simo-
nian and Laird method) was adopted, while the fixed 
effect model was applied in the absence of between-study 
heterogeneity (P > 0.05) (Higgins et al. 2003). In addition, 
we also evaluated the publication bias by Egger linear 
regression test using the funnel plot (Egger et  al. 1997). 
All analyses were conducted with STATA version 12.0 
(StataCorp LP, College Station, Texas, USA).
Results
Study characteristics
A total of 487 studies focusing on the relationship 
between miR-203 and multiple cancers were identified 
in this meta-analysis. The selection process of candidate 
studies was shown in Fig. 1. Finally, 13 studies were con-
sidered eligible for the analysis, among the 13 included 
studies, 3 that evaluated pancreatic cancer (Ikenaga 
et al.2010; Greither et al. 2010; Schultz et al. 2012), 2 that 
evaluated hepatocellular carcinoma (Chen et al. 2012; Liu 
Fig. 1 Flow diagram of the study selection process
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et al. 2015), colorectal cancer (Bovell et al. 2013; Schetter 
et al. 2008) and one each that evaluated glioma(He et al. 
2013), ovarian cancer (Wang et al. 2013a, b), breast can-
cer (Madhavan et al. 2012), gastric cancer (Toiyama et al. 
2015), esophageal carcinoma (Mathe et  al. 2009) and 
ependymoma (Costa et  al. 2011). The main characteris-
tics of these studies are reported in Table 1.
Meta‑analysis
The data of 1600 patients with multiple cancers from 
USA, China, Germany, Japan, Denmark among the 
included studies was summarized for overall survival 
(OS) analysis. Since significant heterogeneity among the 
studies was observed (I2 =  82.8  %, P =  0.000), the ran-
dom effect model was applied to calculate the pooled HR 
and its 95 % CI. Figure 2 displayed the forest plot of the 
analysis about miR-203 and OS. The results showed that 
higher expression levels of miR-203 was not a significant 
predictor of poor OS, with the pooled HR being 1.00 
(95 % CI 0.65–1.36, P = 0.000).
Afterwards we performed subgroup analyses by clas-
sifying each study according to the ethnicity, tumor type 
and miRNA assay method. For the 7 studies focused on 
Asians, high miR-203 expression was found to be signifi-
cantly associated with good OS (HR 0.59, 95 % CI 0.22–
0.96), but for the Caucasians, miR-203 high expression 
was demonstrated to moderately predict poor OS (HR 
1.31, 95 % CI 1.06–1.55) (Fig. 3). When grouped accord-
ing to cancer style of individual studies, as Fig. 4 showed, 
the combined HR of breast cancer, pancreatic cancer and 
ependymoma were 6.35 (95 % CI 1.34–11.36), 1.19 (95 % 
CI 1.08–1.30) and 1.35 (95 % CI 1.10–1.61), respectively, 
indicating that miR-203 was indicators of poor progno-
sis in breast cancer, pancreatic cancer and ependymoma. 
As for glioma, over-expression of miR-203 was predictive 
of better outcome with the HR of 0.26 (95  % CI −0.02 
to 0.54). However, no statistically significant associa-
tions were found in hepatocellular carcinoma, colorectal 
cancer, ovarian cancer, gastric cancer and esophageal 
carcinoma. In the subgroup analysis by miRNA expres-
sion assay method (Fig. 5), there existed significant asso-
ciations between over-expression of miR-203 and poor 
prognosis in direct miRNA profiling studies (HR 6.35, 
95 % CI 1.34–11.36), but no statistically significant asso-
ciations were found in qRT-PCR studies. These subgroup 
analyses results indicated that ethnicity, cancer style and 
miRNA assay method might be the major source of het-
erogeneity. Over-expression of miR-203 in Asians was 
predictive of better outcome, but for Caucasians, it mod-
erately predicted poor OS. For breast cancer, pancreatic 
cancer and ependymoma, high expression of miR-203 
was significantly associated with poor OS. For direct 
miRNA profiling studies, over-expression of miR-203 was 
an independent prognostic factor for worse OS.
Publication bias
Finally, funnel plot and Egger’s test were performed to 
assess the publication bias of the included literature. As 
summarized in Fig. 6, the funnel plots were symmetrical 
well, meanwhile, the P values of the Egger test were 0.804 
for OS, indicating publication bias was not detected in 
the overall analysis of 13 enrolled studies.
Discussion
Recent studies have demonstrated the aberrant expres-
sion of miRNAs in tumors, and specific miRNAs have 
been found to plays crucial roles in cell growth, migra-
tion, invasion and tumor progression (Viticchie et  al. 
2011; Wang et al. 2013a, 2014). Compare to proteins and 
mRNAs, miRNAs are more stable and degrade slower, 
which can be detected as stable markers in serum and 
even in both formalin-fixed and paraffin-embedded tis-
sues. Therefore, miRNAs attract great attention to be an 
effective predictor for early diagnosis and accurate prog-
nosis in cancers.
Among these miRNAs, miR-203 has been frequently 
studied to serve as a tumor suppressor or a tumor pro-
moter in different human cancers. A lot of literatures 
have confirmed that miR-203 contributes to frequent 
tumor-specific CpG-island methylation and is closely 
related to various tumor-associated protein, such as 
ΔNp 63, Akt 2 and ABL 1 to regulate tumor cell prolif-
eration (Furuta et al. 2010; Yuan et al. 2011; Bueno et al. 
2008; Li et al. 2011; Liang et al. 2015). This indicates the 
important relationship between miR-203 expression and 
tumor patient survival. Recently, several studies have 
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observed that significant relationship between elevated 
miR-203 expression and poor overall survival (Schetter 
et al. 2008; Bovell et al. 2013) in colorectal cancer. Gre-
ither et  al. (2010) also reported that high expression of 
miR-203 predicted poor prognosis in pancreatic tumors. 
However, a recent study published by He’s et  al. (2013) 
concluded that overall survival of patients with high miR-
203 expression was significantly longer than those with 
low miR-203 expression. As we know, no meta-analysis 
has focused on the potential prognostic role of miR-203 
in cancer prognosis. Thus, this meta-analysis was carried 
out to evaluate the prognostic value of miR-203 in vari-
ous cancer.
The current meta-analysis has collected 13 articles 
of 1600 patients. In random effect model, the analy-
sis results of forest plot showed that miR-203 might not 
have sufficient power to predict the overall survival of 
cancers, with the pooled HR being 1.00 (95  % CI 0.65–
1.36). In order to explore potential sources of heteroge-
neity, subgroup analyses were performed according to 
ethnicity, cancer types and miRNA assay method. The 
subgroup analysis results suggested that high expression 
of miR-203 was significantly associated with poor OS 
of cancer patients among Caucasians people (HR 1.31, 
95  % CI 1.06–1.55), but in Asians, a better OS associ-
ated with elevated miR-203 expression (HR 0.59, 95 % CI 
0.22–0.96). Based on the analysis results, ethnicity seems 
to play a crucial role in association of miR-203 expres-
sion and cancer patient prognosis, which mainly due to 
the variations in genetic background, environmental fac-
tors. It was also summarized that cancer types have a 
considerable impact on the prognostic role of miR-203. 
Fig. 2 Forest plots of the analyses about miR-203 and overall survival with tumors
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High expression of miR-203 moderately predicted poor 
OS in breast cancer, pancreatic cancer and ependymoma 
patients, but for glioma patients, high miR-203 expres-
sion was significantly associated with better OS. Besides, 
over-expression of miR-203 was an independent prog-
nostic factor for worse OS when direct miRNA profiling 
assay method was used. Generally speaking, our results 
show that miR-203 may not be sufficient to predict can-
cer prognosis and the ethnicity, cancer types and miRNA 
assay method may be the main source of discrepancies.
Nonetheless several limitations exist in the present 
meta-analysis study. First, more and more attention are 
focused on prognostic role of miR-203 in cancer, but the 
studies we included are all from Asians and Caucasians, 
the cancer styles are not comprehensive too; hence, fur-
ther studies explored the prognostic value of miR-203 
on various ethnicities and cancer styles may be needed. 
Secondly, the numerical value of pooled HR was not 
sufficiently strong to indicate the prognosis although 
we have demonstrated the correlation of high miR-203 
expression with the overall survival in Caucasians and 
Asians. Thirdly, we extracted the data form survival 
curves if the studies didn’t provide HR, which might be 
of less credibility compared with direct analysis on HR. 
Fig. 3 Forest plots derived from the analyses of Caucasians and Asians studies
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Despite of the limitations, our study is the first meta-
analysis to evaluate the prognostic role of miR-203 in 
cancer.
Conclusion
In summary, our findings showed that miR-203 may not 
be sufficiently accurate as a prognosis for human can-
cer. But we explored that elevated miR-203 expression 
might potentially predict the poor survival in Cau-
casian people while was significantly correlated with 
good overall survivals in Asians. Besides, tumor type 
and miRNA assay method may be the potential sources 
of heterogeneity. More clinical investigations with 
larger sample size should be conducted to focus on the 
relationship between miR-203 expression and patient 
prognosis.
Fig. 4 Forest plots derived from the analyses of various cancers
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Fig. 5 Forest plots derived from the analyses of different assay methods
Fig. 6 Funnel plots provided graphic estimate of bias for overall studies
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